

Mark W. Kieran

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8227080/publications.pdf>

Version: 2024-02-01

257
papers

20,835
citations

9428

76
h-index

13635

134
g-index

262
all docs

262
docs citations

262
times ranked

25106
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics of patients ≤ 10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry. <i>Neuro-Oncology</i> , 2022, 24, 141-152.	0.6	9
2	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604.	5.8	22
3	ACCELERATE – Five years accelerating cancer drug development for children and adolescents. <i>European Journal of Cancer</i> , 2022, 166, 145-164.	1.3	28
4	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28833.	0.8	9
5	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28787.	0.8	17
6	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). <i>Acta Neuropathologica</i> , 2021, 141, 605-617.	3.9	36
7	The progeria research foundation 10th international scientific workshop; researching possibilities, ExtENDING lives – webinar version scientific summary. <i>Aging</i> , 2021, 13, 9143-9151.	1.4	4
8	Bromodomain and extra-terminal inhibitors – A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children – ACCELERATE. <i>European Journal of Cancer</i> , 2021, 146, 115-124.	1.3	10
9	A global approach to long-term follow-up of targeted and immune-based therapy in childhood and adolescence. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29047.	0.8	8
10	Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future. <i>Child's Nervous System</i> , 2020, 36, 291-296.	0.6	22
11	Outcome of Children Treated for Infantile Hepatic Hemangioendothelioma. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, 126-130.	0.3	13
12	Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children. <i>European Journal of Cancer</i> , 2020, 139, 135-148.	1.3	20
13	Resolution of eicosanoid/cytokine storm prevents carcinogen and inflammation-initiated hepatocellular cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21576-21587.	3.3	48
14	MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. <i>American Journal of Neuroradiology</i> , 2020, 41, 874-881.	1.2	15
15	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. <i>European Journal of Cancer</i> , 2020, 127, 52-66.	1.3	52
16	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	0.6	45
17	Chemotherapy-generated cell debris stimulates colon carcinoma tumor growth via osteopontin. <i>FASEB Journal</i> , 2019, 33, 114-125.	0.2	35
18	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. <i>Nature Communications</i> , 2019, 10, 3731.	5.8	45

#	ARTICLE	IF	CITATIONS
19	Increasing value of autopsies in patients with brain tumors in the molecular era. <i>Journal of Neuro-Oncology</i> , 2019, 145, 349-355.	1.4	6
20	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	5.8	37
21	Hedgehog signaling inhibitors in solid and hematological cancers. <i>Cancer Treatment Reviews</i> , 2019, 76, 41-50.	3.4	90
22	DIPG-02. TRANSLATIONAL MR IMAGING CORRELATES FOR MOLECULAR ANALYSES IN DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). <i>Neuro-Oncology</i> , 2019, 21, ii68-ii68.	0.6	0
23	Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma. <i>Neuro-Oncology</i> , 2019, 21, 537-546.	0.6	61
24	Aspirin-triggered proresolving mediators stimulate resolution in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 6292-6297.	3.3	110
25	Cutaneous reactions to targeted therapies in children with CNS tumors: A cross-sectional study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27682.	0.8	16
26	Efficacy and Safety of Dabrafenib in Pediatric Patients with <i>BRAF</i> V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. <i>Clinical Cancer Research</i> , 2019, 25, 7303-7311.	3.2	128
27	A Phase I and Pharmacokinetic Study of Oral Dabrafenib in Children and Adolescent Patients with Recurrent or Refractory <i>BRAF</i> V600 Mutation-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 7294-7302.	3.2	63
28	Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 1698-1703.	3.3	89
29	Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases. <i>Journal of Clinical Investigation</i> , 2019, 129, 2964-2979.	3.9	94
30	Synergy between Resolvins and Immune Checkpoint Blockade in a Novel Transplantable FANCC ^Δ Murine Head and Neck Tumor Model. <i>FASEB Journal</i> , 2019, 33, 496.10.	0.2	1
31	Cardiac Abnormalities in Patients With Hutchinson-Gilford Progeria Syndrome. <i>JAMA Cardiology</i> , 2018, 3, 326.	3.0	67
32	Microbiome at sites of gingival recession in children with Hutchinson-Gilford progeria syndrome. <i>Journal of Periodontology</i> , 2018, 89, 635-644.	1.7	0
33	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. <i>Neuro-Oncology</i> , 2018, 20, 1101-1112.	0.6	67
34	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	6.0	461
35	Association of Lonafarnib Treatment vs No Treatment With Mortality Rate in Patients With Hutchinson-Gilford Progeria Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1687.	3.8	159
36	Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis. <i>Journal of Pediatrics</i> , 2018, 198, 29-35.e5.	0.9	69

#	ARTICLE	IF	CITATIONS
37	Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26969.	0.8	35
38	Survey of plasma proteins in children with progeria pre-therapy and on-therapy with lonafarnib. <i>Pediatric Research</i> , 2018, 83, 982-992.	1.1	11
39	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 1355-1363.	3.2	24
40	Pubertal Progression in Female Adolescents with Progeria. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2018, 31, 238-241.	0.3	6
41	Response to Harreld re: "Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee". <i>Neuro-Oncology</i> , 2018, 20, 144-145.	0.6	4
42	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <i>Journal of Neuro-Oncology</i> , 2018, 137, 269-278.	1.4	42
43	Desmoplastic nodular medulloblastoma in young children: a management dilemma. <i>Neuro-Oncology</i> , 2018, 20, 1026-1033.	0.6	8
44	Multiparametric Analysis of Permeability and ADC Histogram Metrics for Classification of Pediatric Brain Tumors by Tumor Grade. <i>American Journal of Neuroradiology</i> , 2018, 39, 552-557.	1.2	12
45	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2018, 20, 1547-1555.	0.6	82
46	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. <i>Neuro-Oncology</i> , 2018, 20, 13-23.	0.6	74
47	Resolvins suppress tumor growth and enhance cancer therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 115-140.	4.2	200
48	Pediatric low-grade gliomas: next biologically driven steps. <i>Neuro-Oncology</i> , 2018, 20, 160-173.	0.6	116
49	Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries. <i>Journal of Clinical Oncology</i> , 2018, 36, 1963-1972.	0.8	250
50	LGG-26. TYPE II BRAF INHIBITOR TAK-580 SHOWS PROMISE FOR UPCOMING CLINICAL TRIAL AS EVIDENCED BY SINGLE PATIENT IND STUDY. <i>Neuro-Oncology</i> , 2018, 20, i110-i110.	0.6	7
51	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi204-vi205.	0.6	3
52	LGG-13. RESOLVING TRANSCRIPTIONAL PROFILES IN BRAF-REARRANGED Pilocytic Astrocytoma Using Single Cell RNA Sequencing. <i>Neuro-Oncology</i> , 2018, 20, i107-i107.	0.6	0
53	PATH-17. INCREASING VALUE OF AUTOPSIES IN PATIENTS WITH BRAIN TUMORS IN THE MOLECULAR ERA. <i>Neuro-Oncology</i> , 2018, 20, vi161-vi162.	0.6	0
54	RTHP-08. RE-EVALUATING THE SEQUENCING OF RADIOTHERAPY AND CHEMOTHERAPY IN PEDIATRIC MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi226-vi227.	0.6	0

#	ARTICLE	IF	CITATIONS
55	LGG-44. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS/RAF PATHWAY-ACTIVATED TUMORS. <i>Neuro-Oncology</i> , 2018, 20, i114-i114.	0.6	15
56	DIPG-69. CHARACTERISTICS OF PATIENTS \geq 10 YEARS OF AGE WITH DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE INTERNATIONAL DIPG REGISTRY. <i>Neuro-Oncology</i> , 2018, 20, i63-i63.	0.6	1
57	TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. <i>Neuro-Oncology</i> , 2018, 20, i184-i184.	0.6	0
58	Tumor dissemination through surgical tracts in diffuse intrinsic pontine glioma. <i>Journal of Neurosurgery: Pediatrics</i> , 2018, 22, 678-683.	0.8	9
59	The Integration of Biology Into the Treatment of Diffuse Intrinsic Pontine Glioma: A Review of the North American Clinical Trial Perspective. <i>Frontiers in Oncology</i> , 2018, 8, 169.	1.3	15
60	CRAN-11. MULTIPLEXED IMMUNOFLOUORESCENCE REVEALS POTENTIAL PD-1/PD-L1 PATHWAY VULNERABILITIES IN CRANIOPHARYNGIOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i39.	0.6	2
61	PCLN-07. A 3D HYDROGEL CULTURE SYSTEM FACILITATES STUDY OF PRIMARY PEDIATRIC LOW-GRADE GLIOMA CELLS IN VITRO. <i>Neuro-Oncology</i> , 2018, 20, i156-i156.	0.6	0
62	LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB. <i>Neuro-Oncology</i> , 2018, 20, i114-i114.	0.6	27
63	Dabrafenib in pediatric patients with BRAF V600E-positive high-grade glioma (HGG).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10505-10505.	0.8	12
64	Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600E mutant relapsed refractory low-grade glioma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10506-10506.	0.8	17
65	Suppression of Chemotherapy-induced Cytokine/Eicosanoid Storm and Ovarian Tumor Growth by a Dual COX-2/5-LOX Inhibitor. <i>FASEB Journal</i> , 2018, 32, 281.11.	0.2	0
66	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
67	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. <i>Neuro-Oncology</i> , 2017, 19, now158.	0.6	41
68	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	0.6	217
69	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294.	0.6	54
70	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. <i>Neuro-Oncology</i> , 2017, 19, now261.	0.6	55
71	Long-term neuropsychological follow-up of young children with medulloblastoma treated with sequential high-dose chemotherapy and irradiation sparing approach. <i>Journal of Neuro-Oncology</i> , 2017, 133, 119-128.	1.4	32
72	Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma. <i>Neuro-Oncology</i> , 2017, 19, 1542-1552.	0.6	130

#	ARTICLE	IF	CITATIONS
73	A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26621.	0.8	17
74	Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. <i>Journal of Neuro-Oncology</i> , 2017, 135, 201-211.	1.4	72
75	Ophthalmologic Features of Progeria. <i>American Journal of Ophthalmology</i> , 2017, 182, 126-132.	1.7	7
76	Paucicellular Fibrointimal Proliferation Characterizes Pediatric Pulmonary Vein Stenosis. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1198-1204.	2.1	41
77	Concomitant Use of Panobinostat and Reirradiation in Progressive DIPC: Report of 2 Cases. <i>Journal of Pediatric Hematology/Oncology</i> , 2017, 39, e332-e335.	0.3	12
78	Automated Processing of Dynamic Contrast-Enhanced MRI: Correlation of Advanced Pharmacokinetic Metrics with Tumor Grade in Pediatric Brain Tumors. <i>American Journal of Neuroradiology</i> , 2017, 38, 170-175.	1.2	13
79	A novel GIT2-BRAF fusion in pilocytic astrocytoma. <i>Diagnostic Pathology</i> , 2017, 12, 82.	0.9	26
80	Epigenetics in Clinical Management of Children and Adolescents with Brain Tumors. <i>Current Cancer Drug Targets</i> , 2017, 18, 57-64.	0.8	13
81	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. <i>Journal of Clinical Oncology</i> , 2017, 35, 2934-2941.	0.8	232
82	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 753-763.	1.8	9
83	Lessons learned from diffuse intrinsic pontine glioma: how a terrible disease forced us to think better. <i>Neuro-Oncology</i> , 2017, 19, 1017-1018.	0.6	3
84	TP-0184 Inhibits ALK2/ACVR1, Decreases Hhepcidin Levels, and Demonstrates Activity in Preclinical Mouse Models of Functional Iron Deficiency. <i>Blood</i> , 2017, 130, 937-937.	0.6	2
85	Next generation metronomic chemotherapy report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6-8 May 2016, Mumbai. <i>Ecancermedicalscience</i> , 2016, 10, 689.	0.6	10
86	LG-66CLINICAL AND TREATMENT FACTORS DETERMINING LONG-TERM OUTCOMES FOR ADULT SURVIVORS OF CHILDHOOD LOW-GRADE GLIOMA: A POPULATION-BASED STUDY. <i>Neuro-Oncology</i> , 2016, 18, iii94.1-iii94.	0.6	0
87	The decision-making process and criteria in selecting candidate drugs for progeria clinical trials. <i>EMBO Molecular Medicine</i> , 2016, 8, 685-687.	3.3	7
88	Biopsy for diffuse intrinsic pontine glioma: a reappraisal. <i>Journal of Neurosurgery: Pediatrics</i> , 2016, 18, 390-391.	0.8	10
89	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. <i>Journal of Neuro-Oncology</i> , 2016, 128, 293-302.	1.4	51
90	Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France. <i>Pediatric Blood and Cancer</i> , 2016, 63, 2072-2077.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Clinical, Pathological, and Molecular Characterization of Infant Medulloblastomas Treated with Sequential High-Dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1527-1534.	0.8	94
92	Distinct patterns of primary and motile cilia in Rathke's cleft cysts and craniopharyngioma subtypes. <i>Modern Pathology</i> , 2016, 29, 1446-1459.	2.9	15
93	Clinical Trial of the Protein Farnesylation Inhibitors Lonafarnib, Pravastatin, and Zoledronic Acid in Children With Hutchinson-Gilford Progeria Syndrome. <i>Circulation</i> , 2016, 134, 114-125.	1.6	131
94	Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1. <i>Journal of Neuro-Oncology</i> , 2016, 129, 173-178.	1.4	56
95	Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. <i>Journal of Neuro-Oncology</i> , 2016, 129, 131-138.	1.4	20
96	Clinical and treatment factors determining long-term outcomes for adult survivors of childhood low-grade glioma: A population-based study. <i>Cancer</i> , 2016, 122, 1261-1269.	2.0	109
97	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. <i>Nature Genetics</i> , 2016, 48, 273-282.	9.4	214
98	Myxopapillary ependymomas in children: imaging, treatment and outcomes. <i>Journal of Neuro-Oncology</i> , 2016, 126, 165-174.	1.4	39
99	Future Clinical Trials in DIPG: Bringing Epigenetics to the Clinic. <i>Frontiers in Oncology</i> , 2015, 5, 148.	1.3	50
100	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , 2015, 17, 1486-1496.	0.6	39
101	Pediatric Brainstem Gliomas: New Understanding Leads to Potential New Treatments for Two Very Different Tumors. <i>Current Oncology Reports</i> , 2015, 17, 436.	1.8	49
102	A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors. <i>Child's Nervous System</i> , 2015, 31, 1433-1445.	0.6	14
103	A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 585-593.	3.2	50
104	Time to rethink the unthinkable: Upfront biopsy of children with newly diagnosed diffuse intrinsic pontine glioma (DIPG). <i>Pediatric Blood and Cancer</i> , 2015, 62, 3-4.	0.8	32
105	Abstract 11518: Diastolic Left Ventricular Dysfunction is a Common and Early Cardiac Abnormality in Hutchinson-Gilford Progeria Syndrome. <i>Circulation</i> , 2015, 132, .	1.6	1
106	Targeting BRAF in Pediatric Brain Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e436-e440.	1.8	34
107	The role of the farnesyltransferase inhibitor lonafarnib in the treatment of Progeria. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 95-105.	0.5	3
108	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. <i>Acta Neuropathologica</i> , 2014, 128, 733-741.	3.9	116

#	ARTICLE	IF	CITATIONS
109	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. <i>Nature Genetics</i> , 2014, 46, 462-466.	9.4	381
110	Recurrence after gross-total resection of low-grade pediatric brain tumors: the frequency and timing of postoperative imaging. <i>Journal of Neurosurgery: Pediatrics</i> , 2014, 14, 356-364.	0.8	27
111	Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1598-1602.	0.8	78
112	Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11127-11132.	3.3	84
113	Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Neuro-Oncology</i> , 2014, 16, 707-718.	0.6	93
114	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	7.7	627
115	Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1173-1179.	0.8	210
116	Initial Cutaneous Manifestations of Hutchinson-Gilford Progeria Syndrome. <i>Pediatric Dermatology</i> , 2014, 31, 196-202.	0.5	32
117	Diffuse intrinsic pontine glioma: a reassessment. <i>Journal of Neuro-Oncology</i> , 2014, 119, 7-15.	1.4	99
118	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 294-307.	3.3	45
119	In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. <i>Nature Nanotechnology</i> , 2014, 9, 648-655.	15.6	466
120	BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 912-925.	3.2	296
121	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. <i>Nature Genetics</i> , 2014, 46, 161-165.	9.4	408
122	A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. <i>Pediatric Blood and Cancer</i> , 2014, 61, 636-642.	0.8	120
123	Targeted treatment for sonic hedgehog-dependent medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 1037-1047.	0.6	58
124	Impact of Farnesylation Inhibitors on Survival in Hutchinson-Gilford Progeria Syndrome. <i>Circulation</i> , 2014, 130, 27-34.	1.6	186
125	Recurrent Ascites in a Patient With Low-grade Astrocytoma and Ventriculo-Peritoneal Shunt Treated With the Multikinase Inhibitor Sorafenib. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e533-e535.	0.3	4
126	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	9.4	674

#	ARTICLE	IF	CITATIONS
127	Challenges with defining response to antitumor agents in pediatric neuro-oncology: A report from the response assessment in pediatric neuro-oncology (RAPNO) working group. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1397-1401.	0.8	64
128	Specific uptake of ^{99m} Tc-NC100692, an $\alpha^2\beta^2$ -targeted imaging probe, in subcutaneous and orthotopic tumors. <i>Nuclear Medicine and Biology</i> , 2013, 40, 788-794.	0.3	21
129	Role of Collagen Matrix in Tumor Angiogenesis and Glioblastoma Multiforme Progression. <i>American Journal of Pathology</i> , 2013, 183, 1293-1305.	1.9	143
130	The growing role of eicosanoids in tissue regeneration, repair, and wound healing. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 104-105, 130-138.	1.0	29
131	Predictors of neoplastic disease in children with isolated pituitary stalk thickening. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1630-1635.	0.8	29
132	Future of Clinical Genomics in Pediatric Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 1893-1903.	0.8	40
133	A phase I pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: A pediatric brain tumor consortium study. <i>Pediatric Blood and Cancer</i> , 2013, 60, 627-632.	0.8	20
134	Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. <i>Neurology</i> , 2013, 81, 427-430.	1.5	52
135	New Strategies in Pediatric Gliomas: Molecular Advances in Pediatric Low-Grade Gliomas as a Model. <i>Clinical Cancer Research</i> , 2013, 19, 4553-4558.	3.2	31
136	Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: A report from the Children's Oncology Group. <i>Neuro-Oncology</i> , 2013, 15, 1438-1444.	0.6	36
137	A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. <i>Neuro-Oncology</i> , 2013, 15, 462-468.	0.6	119
138	Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 6530-6535.	3.3	251
139	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i> . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8188-8193.	3.3	188
140	Epoxyeicosanoids promote organ and tissue regeneration. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 13528-13533.	3.3	124
141	Epoxyeicosanoid regulation of tumor lymphangiogenesis. <i>FASEB Journal</i> , 2013, 27, lb457.	0.2	0
142	Mechanisms of Premature Vascular Aging in Children With Hutchinson-Gilford Progeria Syndrome. <i>Hypertension</i> , 2012, 59, 92-97.	1.3	125
143	The VEGF Pathway in Cancer and Disease: Responses, Resistance, and the Path Forward. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006593-a006593.	2.9	165
144	Inhibition of neuroblastoma cell proliferation with omega-3 fatty acids and treatment of a murine model of human neuroblastoma using a diet enriched with omega-3 fatty acids in combination with sunitinib. <i>Pediatric Research</i> , 2012, 71, 168-178.	1.1	19

#	ARTICLE	IF	CITATIONS
145	Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16666-16671.	3.3	315
146	Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma. European Journal of Cancer, 2012, 48, 253-262.	1.3	130
147	Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatric Blood and Cancer, 2012, 59, 1155-1157.	0.8	75
148	A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. Pediatric Radiology, 2012, 42, 1089-1098.	1.1	26
149	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. PLoS ONE, 2012, 7, e38881.	1.1	28
150	Identification of Novel Biologic Targets in the Treatment of Newly Diagnosed Diffuse Intrinsic Pontine Glioma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 625-628.	1.8	3
151	Sleep dysfunction in long term survivors of craniopharyngioma. Journal of Neuro-Oncology, 2012, 108, 543-549.	1.4	45
152	Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). Journal of Neuro-Oncology, 2012, 109, 565-571.	1.4	24
153	Bone density in post-pubertal adolescent survivors of childhood brain tumors. Pediatric Blood and Cancer, 2012, 58, 959-963.	0.8	34
154	Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors. Pediatric Blood and Cancer, 2012, 59, 511-517.	0.8	98
155	Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatric Blood and Cancer, 2012, 58, 489-491.	0.8	111
156	Differences in molecular genetics between pediatric and adult malignant astrocytomas: age matters. Future Oncology, 2012, 8, 549-558.	1.1	18
157	Pediatric neuro-oncology: Current status and future directions. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 223-231.	0.7	17
158	Abstract 4818: The predictive value of a 5-gene signature as a patient pre-selection tool in medulloblastoma for Hedgehog pathway inhibitor therapy. Cancer Research, 2012, 72, 4818-4818.	0.4	6
159	Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. Journal of Clinical Investigation, 2012, 122, 178-191.	3.9	242
160	A phase I/II study of LDE225, a smoothed (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.. Journal of Clinical Oncology, 2012, 30, 9519-9519.	0.8	21
161	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. Journal of Molecular Diagnostics, 2011, 13, 669-677.	1.2	81
162	Moving Forward with Metronomic Chemotherapy: Meeting Report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Translational Oncology, 2011, 4, 203-211.	1.7	35

#	ARTICLE	IF	CITATIONS
163	Pediatric Tumors. , 2011, , 285-332.		1
164	A Prospective Phase II Trial of Vinblastine and Methotrexate in Multivessel Intraluminal Pulmonary Vein Stenosis in Infants and Children. <i>Congenital Heart Disease</i> , 2011, 6, 608-623.	0.0	46
165	Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2011, 104, 179-189.	1.4	29
166	Parent-perceived child cognitive function: results from a sample drawn from the US general population. <i>Child's Nervous System</i> , 2011, 27, 285-293.	0.6	31
167	DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy. <i>Child's Nervous System</i> , 2011, 27, 11-18.	0.6	46
168	Long-term clinical outcomes following treatment of childhood craniopharyngioma. <i>Pediatric Blood and Cancer</i> , 2011, 56, 1120-1126.	0.8	59
169	Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. <i>Proteomics</i> , 2011, 11, 935-943.	1.3	54
170	Hutchinson-gilford progeria is a skeletal dysplasia. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 1670-1679.	3.1	69
171	Association of Rapidly Progressive Moyamoya Syndrome With Bevacizumab Treatment for Glioblastoma in a Child With Neurofibromatosis Type 1. <i>Journal of Child Neurology</i> , 2011, 26, 228-230.	0.7	18
172	Development of a Parent-Report Cognitive Function Item Bank Using Item Response Theory and Exploration of its Clinical Utility in Computerized Adaptive Testing. <i>Journal of Pediatric Psychology</i> , 2011, 36, 766-779.	1.1	51
173	A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. <i>Neuro-Oncology</i> , 2011, 13, 820-829.	0.6	29
174	Inhibition of tumor angiogenesis by oral etoposide. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 739-746.	0.8	44
175	Biological modification strategies following marrow ablative, high-dose chemotherapy (HDCT) with autologous hematopoietic stem cell rescue (AHSCR) for pediatric brain tumors. <i>Pediatric Blood and Cancer</i> , 2010, 54, 654-656.	0.8	2
176	Clinicopathologic study of glioblastoma in children with neurofibromatosis type 1. <i>Pediatric Blood and Cancer</i> , 2010, 54, 890-896.	0.8	59
177	Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. <i>Molecular Cancer</i> , 2010, 9, 277.	7.9	57
178	A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. <i>European Journal of Cancer</i> , 2010, 46, 3287-3293.	1.3	59
179	Brain Tumors: From Childhood Through Adolescence Into Adulthood. <i>Journal of Clinical Oncology</i> , 2010, 28, 4783-4789.	0.8	73
180	Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. <i>Neuro-Oncology</i> , 2009, 11, 109-121.	0.6	111

#	ARTICLE	IF	CITATIONS
181	Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 973-983.	1.9	14
182	Host Factor Vulnerability and Development of Progressive Intraluminal Pulmonary Vein Stenosis after Congenital Heart Surgery. <i>Congenital Heart Disease</i> , 2009, 4, 86-90.	0.0	3
183	Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2009, 52, 169-176.	0.8	38
184	Small molecule inhibitors in children with malignant gliomas. <i>Pediatric Blood and Cancer</i> , 2009, 53, 312-317.	0.8	15
185	A prospective, blinded analysis of A α PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors. <i>Pediatric Blood and Cancer</i> , 2009, 53, 343-347.	0.8	2
186	Medical, psychological, cognitive and educational late α effects in pediatric low α grade glioma survivors treated with surgery only. <i>Pediatric Blood and Cancer</i> , 2009, 53, 417-423.	0.8	55
187	Platelets actively sequester angiogenesis regulators. <i>Blood</i> , 2009, 113, 2835-2842.	0.6	302
188	Intensive Multimodality Treatment for Children With Newly Diagnosed CNS Atypical Teratoid Rhabdoid Tumor. <i>Journal of Clinical Oncology</i> , 2009, 27, 385-389.	0.8	397
189	Metachronous Mediastinal Seminoma Occurring After Intracranial Germinoma in an Adolescent. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 861-864.	0.3	2
190	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. <i>PLoS ONE</i> , 2009, 4, e7887.	1.1	316
191	Tumors of the Brain and Spinal Cord. , 2009, , 601-720.		2
192	Type IV collagen α 6 chain α derived noncollagenous domain 1 (α 6(IV)NC1) inhibits angiogenesis and tumor growth. <i>International Journal of Cancer</i> , 2008, 122, 1738-1744.	2.3	38
193	Outcome of pediatric pineoblastoma after surgery, radiation and chemotherapy. <i>Journal of Neuro-Oncology</i> , 2008, 89, 89-95.	1.4	63
194	Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 15040-15045.	3.3	69
195	Anti-Apoptosis Mechanisms in Malignant Gliomas. <i>Journal of Clinical Oncology</i> , 2008, 26, 493-500.	0.8	87
196	Basement Membrane Derived Fibulin-1 and Fibulin-5 Function as Angiogenesis Inhibitors and Suppress Tumor Growth. <i>Experimental Biology and Medicine</i> , 2008, 233, 155-162.	1.1	56
197	Prognostic Value of Tumor Microinvasion and Metalloproteinases Expression in Intracranial Pediatric Ependymomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2008, 67, 911-920.	0.9	26
198	PPAR α agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 985-990.	3.3	249

#	ARTICLE	IF	CITATIONS
199	Phase I Clinical Trial of Cilengitide in Children With Refractory Brain Tumors: Pediatric Brain Tumor Consortium Study PBTC-012. <i>Journal of Clinical Oncology</i> , 2008, 26, 919-924.	0.8	143
200	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. <i>Neuro-Oncology</i> , 2008, 10, 300-308.	0.6	88
201	Remission of Infantile Generalized Myofibromatosis After Interferon Alpha Therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2008, 30, 179-181.	0.3	15
202	PPARs: A Double-Edged Sword in Cancer Therapy?. <i>PPAR Research</i> , 2008, 2008, 1-2.	1.1	18
203	Prognostic value of tumor microinvasion and metalloproteinases expression in intracranial pediatric ependymomas. <i>FASEB Journal</i> , 2008, 22, 706.8.	0.2	0
204	Phase I and Pharmacokinetic Study of the Oral Farnesyltransferase Inhibitor Lonafarnib Administered Twice Daily to Pediatric Patients With Advanced Central Nervous System Tumors Using a Modified Continuous Reassessment Method: A Pediatric Brain Tumor Consortium Study. <i>Journal of Clinical Oncology</i> , 2007, 25, 3137-3143.	0.8	67
205	Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. <i>Neuro-Oncology</i> , 2007, 9, 354-363.	0.6	101
206	Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report1. <i>Neuro-Oncology</i> , 2007, 9, 145-160.	0.6	169
207	Disease Progression in Hutchinson-Gilford Progeria Syndrome: Impact on Growth and Development. <i>Pediatrics</i> , 2007, 120, 824-833.	1.0	105
208	New Approaches to Progeria. <i>Pediatrics</i> , 2007, 120, 834-841.	1.0	83
209	BRAINSTEM LESIONS IN NEUROFIBROMATOSIS TYPE 1. <i>Neurosurgery</i> , 2007, 61, 762-767.	0.6	74
210	Phase II study of thalidomide and radiation in children with newly diagnosed brain stem gliomas and glioblastoma multiforme. <i>Journal of Neuro-Oncology</i> , 2007, 82, 95-101.	1.4	61
211	PPAR δ Deficiency in Inflammatory Cells Suppresses Tumor Growth. <i>PLoS ONE</i> , 2007, 2, e260.	1.1	87
212	Pulmonary vein stenosis: expression of receptor tyrosine kinases by lesional cells. <i>Cardiovascular Pathology</i> , 2006, 15, 91-99.	0.7	76
213	Everyday Cognitive Function After Craniopharyngioma in Childhood. <i>Pediatric Neurology</i> , 2006, 34, 13-19.	1.0	55
214	Transverse Myelitis After Therapy For Primitive Neuroectodermal Tumors. <i>Pediatric Neurology</i> , 2006, 35, 122-125.	1.0	12
215	AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma. <i>Cancer Research</i> , 2006, 66, 8722-8730.	0.4	54
216	Don't Throw Out the Baby With the Bathwater!. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 59-60.	0.3	2

#	ARTICLE	IF	CITATIONS
217	A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer. <i>Journal of Pediatric Hematology/Oncology</i> , 2005, 27, 573-581.	0.3	187
218	PPAR γ 3 as a therapeutic target for tumor angiogenesis and metastasis. <i>Cancer Biology and Therapy</i> , 2005, 4, 687-693.	1.5	122
219	Stereotactic radiotherapy for localized low-grade gliomas in children: Final results of a prospective trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 374-379.	0.4	132
220	Cutaneous visceral Angiomas with Thrombocytopenia. <i>Pediatric and Developmental Pathology</i> , 2005, 8, 407-419.	0.5	58
221	Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. <i>Journal of Neuro-Oncology</i> , 2005, 72, 77-84.	1.4	90
222	Anti-angiogenic Therapy in Pediatric Neuro-oncology. <i>Journal of Neuro-Oncology</i> , 2005, 75, 327-334.	1.4	15
223	ZD6474, a Novel Tyrosine Kinase Inhibitor of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor, Inhibits Tumor Growth of Multiple Nervous System Tumors. <i>Clinical Cancer Research</i> , 2005, 11, 8145-8157.	3.2	94
224	Diencephalic Syndrome: A Cause of Failure to Thrive and a Model of Partial Growth Hormone Resistance. <i>Pediatrics</i> , 2005, 115, e742-e748.	1.0	101
225	Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 2934-2939.	3.3	170
226	Phase I Clinical Trial of Mafosfamide in Infants and Children Aged 3 Years or Younger With Newly Diagnosed Embryonal Tumors: A Pediatric Brain Tumor Consortium Study (PBTC-001). <i>Journal of Clinical Oncology</i> , 2005, 23, 525-531.	0.8	42
227	The rationale for nonsteroidal anti-inflammatory drug therapy for inflammatory myofibroblastic tumors: a Children's Oncology Group study. <i>Journal of Pediatric Surgery</i> , 2005, 40, 999-1003.	0.8	91
228	Perfusion MRI of U87 brain tumors in a mouse model. <i>Magnetic Resonance in Medicine</i> , 2004, 51, 893-899.	1.9	64
229	Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model. <i>NMR in Biomedicine</i> , 2004, 17, 399-404.	1.6	25
230	Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression. <i>Cancer Research</i> , 2004, 64, 1570-1574.	0.4	175
231	Treatment of low-grade gliomas in children: an update. <i>Expert Review of Neurotherapeutics</i> , 2004, 4, 1005-1014.	1.4	6
232	Anti-angiogenic Chemotherapy in Central Nervous System Tumors. <i>Cancer Treatment and Research</i> , 2004, 117, 337-349.	0.2	19
233	Psychosocial and behavioral functioning among pediatric brain tumor survivors. <i>Journal of Neuro-Oncology</i> , 2003, 63, 279-287.	1.4	81
234	Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. <i>Medical and Pediatric Oncology</i> , 2003, 41, 516-526.	1.0	23

#	ARTICLE	IF	CITATIONS
235	A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 55, 1182-1185.	0.4	51
236	Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria. <i>Journal of Biological Chemistry</i> , 2003, 278, 12605-12608.	1.6	472
237	Chemotherapy for Progressive Low-Grade Gliomas in Children Older than Ten Years: The Dana-Farber Experience. <i>Pediatric Hematology and Oncology</i> , 2003, 20, 497-504.	0.3	22
238	Therapeutic potential of thiazolidinediones as anticancer agents. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 1925-1937.	1.9	75
239	A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 13513-13518.	3.3	590
240	Marked Regression of Metastatic Pilocytic Astrocytoma During Treatment With Imatinib Mesylate (STI-571, Gleevec): A Case Report and Laboratory Investigation. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 644-648.	0.3	21
241	Neuropsychological Functioning after Surgery in Children Treated for Brain Tumor. <i>Neurosurgery</i> , 2003, 52, 1348-1357.	0.6	52
242	Psychological adjustment of ?surgery-only? pediatric neuro-oncology patients: a retrospective analysis. <i>Psycho-Oncology</i> , 2002, 11, 74-79.	1.0	31
243	Non-cell autonomous requirement for the bloodless gene in primitive hematopoiesis of zebrafish. <i>Development (Cambridge)</i> , 2002, 129, 649-659.	1.2	57
244	Antiangiogenic therapy and p53. <i>Science</i> , 2002, 297, 471; discussion 471.	6.0	4
245	ANTIANGIOGENESIS THERAPY. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 835-852.	0.9	20
246	Memory Deficits among Children with Craniopharyngiomas. <i>Neurosurgery</i> , 2001, 49, 1053-1058.	0.6	71
247	Memory Deficits among Children with Craniopharyngiomas. <i>Neurosurgery</i> , 2001, 49, 1053-1058.	0.6	76
248	Myelopoiesis in the zebrafish, <i>Danio rerio</i> . <i>Blood</i> , 2001, 98, 643-651.	0.6	391
249	Stereotactic radiotherapy for pediatric intracranial germ cell tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 108-112.	0.4	26
250	Advances in pediatric neuro-oncology. <i>Current Opinion in Neurology</i> , 2000, 13, 627-634.	1.8	5
251	Mechanism of pulmonary vein stenosis in infants with normally connected veins. <i>American Journal of Cardiology</i> , 2000, 86, 577-579.	0.7	123
252	Innovative therapies for pediatric brain tumors. <i>Current Opinion in Pediatrics</i> , 1999, 11, 33-38.	1.0	7

#	ARTICLE	IF	CITATIONS
253	The cloche and spadetail genes differentially affect hematopoiesis and vasculogenesis. <i>Developmental Biology</i> , 1998, 197, 248-269.	0.9	467
254	Portohepatic shunt in a down syndrome patient with an interchange trisomy 47,XY,â²2,+der(2),+der(21)t(2;21)(p13;q22.1)mat. <i>American Journal of Medical Genetics Part A</i> , 1992, 44, 288-292.	2.4	14
255	The DNA binding subunit of NF-Î²B is identical to factor KBF1 and homologous to the rel oncogene product. <i>Cell</i> , 1990, 62, 1007-1018.	13.5	980
256	Two purified factors bind to the same sequence in the enhancer of mouse MHC class I genes: one of them is a positive regulator induced upon differentiation of teratocarcinoma cells. <i>Nucleic Acids Research</i> , 1989, 17, 5245-5258.	6.5	73
257	Correlation of erythrocytic peripheral blood chimaerism and putative bone marrow precursors bearing erythroid differentiation (B-C) antigens using monoclonal antibodies immobilized on fluorescent latex spheres. <i>Journal of Immunological Methods</i> , 1984, 66, 349-356.	0.6	7